Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: RTOG 0815 A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER

 


RTOG 0815 A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER


Trial Focus

Prostate Cancer

Objective

         The purpose of this study is to compare the effects of dose-escalated radiation therapy with or without hormone therapy on your prostate cancer.

IRB Protocol #

10-1101

Trial Status

OPEN

Principle Investigator

DAVID RABEN

Sponsor

RTOG

Contact

MONICA ROBISCHON at (720) 848-0661 or MONICA.ROBISCHON@UCDENVER.EDU

Location

Dept Of Veterans Affairs Medical Center ST. MARYS HOSPITAL - G.J. University of Colorado Hospital Dept Of Veterans Affairs Medical Center ST. MARYS HOSPITAL - G.J. University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : Patients will receive 44 radiation treatments over approximately 2 months. With the brachytherapy implant, patients will receive 25 daily treatments plus the implant procedure over a timeframe of approximately 6 weeks. Hormone therapy, if given, will last 6 months. Patients will be followed for life. // Eligibility criteria : A screening period to determine eligibility. A treatment period (s) that can last up to (duration from ICF). A follow up period will consist of (phone contact, physician contact, or clinic visit).Eligibility criteria : A screening period to determine eligibility. A treatment period (s) that can last up to (duration from ICF). A follow up period will consist of (phone contact, physician contact, or clinic visit).